
Abeona Therapeutics (ABEO) Stock Forecast & Price Target
Abeona Therapeutics (ABEO) Analyst Ratings
Bulls say
Abeona Therapeutics is benefiting from early commercial traction in ZEVASKYN, with 15 patient treatments completed since launch, including six in the most recently completed quarter, and a broader QTC network now spanning eight sites that should expand geographic access and accelerate adoption. The New Technology Add-On Payment status effective October 1, 2026 is an important reimbursement catalyst that can improve hospital economics for eligible Medicare beneficiaries, while 3Q26 revenue of $13.5M and $134.9M in cash, cash equivalents and marketable securities support execution through to cash flow break-even. Beyond the launch, the ABO-801 acquisition and $30M private placement add a Phase 3-ready pipeline asset without upfront cash at closing, strengthening longer-term growth optionality.
Bears say
Abeona Therapeutics is facing a negative outlook because lower-than-expected near-term revenues and higher operating expenses are pressuring the model, while reimbursement risk remains elevated for one of the most expensive classes of medicine. Its pipeline also carries substantial clinical and regulatory uncertainty, with prior Phase 3 setbacks that missed both co-primary symptom endpoints and a new program that sits in a “show me” category with high trial risk. Even with management’s assurances that the added pipeline asset will not divert resources from ZEVASKYN, the company is taking on an entirely new, higher-risk therapeutic vertical amid manufacturing and payor resistance concerns.
This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Abeona Therapeutics (ABEO) Analyst Forecast & Price Prediction
Start investing in Abeona Therapeutics (ABEO)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Abeona Therapeutics (ABEO) Forecast
Abeona Therapeutics (ABEO) Analyst Forecast & Price Prediction
Start investing in Abeona Therapeutics (ABEO)
Order type
Buy in
Order amount
Est. shares
0 shares